Stockscreener 앱 받기
14.11
3.52%
0.48
전일 마감가:
$13.63
열려 있는:
$13.79
하루 거래량:
1.82M
Relative Volume:
0.74
시가총액:
$1.68B
수익:
$59.61M
순이익/손실:
$-262.14M
주가수익비율:
-3.5995
EPS:
-3.92
순현금흐름:
$-247.49M
1주 성능:
+4.29%
1개월 성능:
+8.87%
6개월 성능:
+52.38%
1년 성능:
+54.71%
1일 변동 폭
$13.57
$14.19
1주일 범위
$13.31
$14.61
52주 변동 폭
$6.99
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
명칭
Arcutis Biotherapeutics Inc
전화
805-418-5006
주소
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
14.11 | 1.61B | 59.61M | -262.14M | -247.49M | -3.92 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-10-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-09-07 | 개시 | Needham | Buy |
| 2022-03-17 | 개시 | Goldman | Buy |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-05-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-02-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 개시 | Cowen | Outperform |
| 2020-02-25 | 개시 | Goldman | Neutral |
| 2020-02-25 | 개시 | Guggenheim | Buy |
모두보기
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
When the Price of (ARQT) Talks, People Listen - news.stocktradersdaily.com
ARQT: Key Insights from Genital Psoriasis Consensus Statements | - GuruFocus
New Consensus Statements on Impact of Genital Psoriasis on Patie - GuruFocus
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice - The Manila Times
Arcutis Biotherapeutics Publishes Expert Consensus on Genital Psoriasis to Enhance Patient Care and Treatment Decision-Making - Nasdaq
Medical Breakthrough: Experts Release 14 Game-Changing Guidelines for Genital Psoriasis Treatment - Stock Titan
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy - openPR.com
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics - Barchart.com
Director’s Bold Move: A Major Investment in Arcutis Biotherapeutics - TipRanks
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and AMN Healthcare Services (AMN) - The Globe and Mail
Arcutis outlines growth potential with ZORYVE expansions and market penetration - MSN
Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates - MSN
Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements - Yahoo Finance
Arcutis Biotherapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2025 Earnings Call Transcript - Insider Monkey
Arcutis Biotherapeutics Reports Strong Q1 Earnings Growth - TipRanks
Jefferies lifts Arcutis stock target to $20 on strong sales By Investing.com - Investing.com South Africa
ZORYVE foam shows promise in psoriasis treatment By Investing.com - Investing.com South Africa
ZORYVE foam shows promise in psoriasis treatment - Investing.com
Arcutis Announces Publication of Positive Data from ARRECTOR Tri - GuruFocus
Arcutis Biotherapeutics (ARQT) Reports Positive Phase 3 Trial Results for Psoriasis Treatment | ARQT Stock News - GuruFocus
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology - The Manila Times
Arcutis Announces Publication of Positive Data from Arrector Trial Evaluating Zoryve®? (Roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology - marketscreener.com
Jefferies lifts Arcutis stock target to $20 on strong sales - Investing.com Australia
Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Decoding Arcutis Biotherapeutics Inc (ARQT): A Strategic SWOT In - GuruFocus
Arcutis Biotherapeutics Reports Strong Q1 2025 Growth - TipRanks
Arcutis (ARQT) Reports Strong Q1 Growth on Rising ZORYVE Demand - GuruFocus
Earnings call transcript: Arcutis Biotherapeutics Q1 2025 earnings beat estimates - Investing.com
Earnings call transcript: Arcutis Biotherapeutics Q1 2025 earnings beat estimates By Investing.com - Investing.com India
Arcutis Biotherapeutics stock falls despite Q1 revenue beat By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics stock falls despite Q1 revenue beat - Investing.com
Arcutis Biotherapeutics (ARQT) Q1 Performance Surpasses Expectations - GuruFocus
Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings: EPS Loss of $0.20 Beats Estimate, Revenue Surpasses Forecast at $63.8 Million - GuruFocus
Arcutis Q1 2025 slides: Revenue soars 196% YoY despite seasonal headwinds - Investing.com India
ARCUTIS BIOTHERAPEUTICS Earnings Results: $ARQT Reports Quarterly Earnings - Nasdaq
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Arcutis Biotherapeutics (ARQT) Surpasses Q1 Revenue Expectations with Robust Growth | ARQT Stock News - GuruFocus
Earnings Flash (ARQT) Arcutis Biotherapeutics Reports Q1 Revenue $65.8M, vs. FactSet Est of $62.2M - marketscreener.com
Arcutis Q1 Earnings: ZORYVE Sales Surge 196% to $64M as Coverage Expands | ARQT Stock News - Stock Titan
Arcutis Biotherapeutics (ARQT) Q1 Earnings Preview - GuruFocus
How to Take Advantage of moves in (ARQT) - news.stocktradersdaily.com
What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q1 2025 E - GuruFocus
Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com
What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings - GuruFocus
Arcutis Biotherapeutics Inc (ARQT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):